


Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology® 2020;:1. doi:10.1212/WNL.0000000000008927

In the article “Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients” by Plavina et al.,¹ there is an error in the “Monocyte/VCAM-1 binding” key of figure 3. “Natalizumab continued” should have been represented by a green line and gray square; “Natalizumab interrupted” should have been represented by a red line and black circle. The editorial office regrets the errors.

Figure 3 Functional activity of CD3+ T cells, CD19+ B cells, and monocytes from RESTORE patients



Reference

1. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. *Neurology* 2017;89:1584–1593.

Neurology®

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology published online September 16, 2020
DOI 10.1212/WNL.00000000000008927

This information is current as of September 16, 2020

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2020/09/16/WNL.00000000000008927.citation.full
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

